July, 2019

Publication of the 2019 Half-Yearly Financial Report

Paris (France), July 31, 2019 – 7.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced the publication of the Company’s 2019 half-yearly financial report….read more →

Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update

Finalization of DRIIV-1 Phase 1 study confirming AsiDNA™ activity and safety profile Initiation of DRIIV-1b study of AsiDNA™ with chemotherapy, on track with preliminary results expected end H2 2019 and final results in H1 2020 New optimized lead OX401 undergoing proof-of-concept preclinical studies Cash position of €6.3 million at June 30, 2019 complemented by the Nice & Green equity line,…read more →

AsiDNA™ Letter – No. 2

AsiDNA™ Letter – No. 2 Role of AsiDNA™ in the new combination strategies Ladies, Gentlemen and shareholders The complexity and diversity of cancers require multiple therapeutic approaches. The combination of several anti-cancer agents has become the norm in oncology, especially to treat the very aggressive or resistant cancers. Thanks to its original anti-tumor activity and its good tolerance already clinically demonstrated, AsiDNA™ is…read more →

AsiDNA™ Letter – No. 1

Ladies, Gentlemen and Shareholders, The clinical development of AsiDNA™ is well on its way and we would like to inform you regularly about the progress being made through a Letter dedicated to this first-in-class candidate. In this first issue, we go back to the fundamentals of the DNA Damage Response (DDR) therapeutic approach in oncology, which consists of fighting cancer…read more →

The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a “Buy” recommendation

Paris (France), July 1st, 2019 – 7:00 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (hereinafter “Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced the publication of an initiation report by KEPLER CHEUVREUX, a…read more →